This Low-Debt Multibagger Small-Cap Pharma Stock Jumps 13% as the Company Enters the Fast-Growing Hospital Segment Through a Strategic Acquisition

On Tuesday, Indian benchmark indices traded lower, with the Nifty 50 declining 50.40 points, or 0.21 per cent, to 23,895.85. Despite the weak market sentiment, Jagsonpal Pharmaceuticals jumped 12.89 per cent to Rs 260.05 after the company announced the acquisition of a majority stake in Aequitas Healthcare Private Limited, strengthening its presence in the institutional healthcare market.

Jagsonpal Enters Hospital Pharma Segment

Jagsonpal Pharmaceuticals has entered into a definitive agreement to acquire an 85 per cent equity stake in Mumbai-based Aequitas Healthcare Private Limited for Rs 20.8 crore. The acquisition will be funded through the company's internal accruals and is expected to be completed by July 15, 2026, subject to customary closing conditions. Following the transaction, the existing directors of Aequitas will retain the remaining 15 per cent stake and continue to be associated with the business.

Founded in 2017, Aequitas Healthcare is engaged in the sale and distribution of pharmaceutical products to hospitals and has established relationships with leading hospital chains across India. The company reported FY26 revenue of Rs 53 crore, providing Jagsonpal with an established platform to expand into the institutional pharmaceutical market.

Strategic Expansion into a High-Growth Segment

The acquisition marks Jagsonpal's strategic entry into the hospital pharmaceutical business. This segment currently contributes nearly 10 per cent of the Indian pharmaceutical industry's sales and is growing faster than the traditional retail prescription market.

Commenting on the acquisition, Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals, said, "The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes ~10% of pharma industry sales and growing faster. We strongly believe that Jagsonpal's portfolio of established brands will greatly benefit from Aequitas' strong institutional relationships, delivering sustainable long-term value to our shareholders."
Also Read - 127% Return in 1 Year: This Pharma Company Approves Rs 100 Crore Change in IPO Fund Utilisation; Check Details

Management Sees Structural Transformation

Highlighting the strategic significance of the transaction, Amrut Medhekar, Chief Operating Officer of Jagsonpal Pharmaceuticals, said, "This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India. We look forward to unlocking value through operational excellence, disciplined execution, and patient-centric growth."

Shailesh Kamat, Director and largest shareholder of Aequitas Healthcare, added that the company has built a strong hospital business with quality products and deep institutional relationships over the past eight years. He said the partnership with Jagsonpal would help accelerate Aequitas' next phase of growth while creating value for employees, customers and stakeholders.

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company with a track record of more than five decades in the domestic pharmaceutical market. The company has a strong portfolio focused on Gynaecology, Orthopaedics and Dermatology, with more than 20 brands ranked among the top five in their respective molecule categories.

Backed by an experienced sales force of over 1,000 professionals and a pan-India presence, the company has built several market-leading prescription brands. The acquisition of Aequitas marks an important step in expanding beyond its traditional retail prescription business into the rapidly growing hospital and institutional healthcare segment.

What are your thoughts on Jagsonpal Pharmaceuticals' strategic acquisition of Aequitas Healthcare? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.